|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
63,980,000 |
Market
Cap: |
586.70(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.22 - $11.59 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 245 |
Guru Rank Value : 4.8 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
Total People Sold |
1 |
2 |
2 |
4 |
Total Sell Transactions |
1 |
3 |
11 |
21 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
349,233 |
|
- |
|
Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
|
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
360,684 |
|
- |
|
Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
|
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
338,636 |
|
- |
|
Miller Aine |
SVP, DEV & HEAD OF IRE OFFICE |
|
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
171,034 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
1,850,573 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2024-03-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
3,900 |
3,900 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2024-03-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,900 |
1,550,573 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2024-03-15 |
4 |
A |
$8.64 |
$23,363 |
D/D |
2,704 |
1,561,473 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2024-02-22 |
4 |
AS |
$8.71 |
$10,922 |
D/D |
(1,254) |
311,733 |
|
8% |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2024-02-20 |
4 |
D |
$8.92 |
$162,513 |
D/D |
(18,219) |
312,987 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2024-02-20 |
4 |
D |
$8.92 |
$331,788 |
D/D |
(37,196) |
1,558,769 |
|
- |
|
Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
|
2024-02-20 |
4 |
D |
$8.92 |
$172,102 |
D/D |
(19,294) |
314,915 |
|
- |
|
Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
|
2024-02-20 |
4 |
D |
$8.92 |
$151,961 |
D/D |
(17,036) |
238,636 |
|
- |
|
Miller Aine |
SVP, DEV & HEAD OF IRE OFFICE |
|
2024-02-20 |
4 |
D |
$8.92 |
$105,095 |
D/D |
(11,782) |
133,534 |
|
- |
|
Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
|
2024-02-20 |
4 |
D |
$8.92 |
$156,947 |
D/D |
(17,595) |
260,684 |
|
- |
|
Miller Aine |
SVP, Dev & Head of IRE Office |
|
2024-02-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
145,316 |
|
5% |
|
Grant Jeremy T |
|
|
2023-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
11,768 |
11,768 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2023-11-21 |
4 |
AS |
$10.29 |
$14,180 |
D/D |
(1,378) |
331,206 |
|
-10% |
|
Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
|
2023-11-20 |
4 |
D |
$10.37 |
$76,354 |
D/D |
(7,363) |
278,279 |
|
- |
|
Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
|
2023-11-20 |
4 |
D |
$10.37 |
$64,159 |
D/D |
(6,187) |
255,672 |
|
- |
|
Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
|
2023-11-20 |
4 |
D |
$10.37 |
$130,973 |
D/D |
(12,630) |
334,209 |
|
- |
|
Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
|
2023-11-20 |
4 |
D |
$10.37 |
$163,887 |
D/D |
(15,804) |
1,595,965 |
|
- |
|
Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
|
2023-11-20 |
4 |
D |
$10.37 |
$82,773 |
D/D |
(7,982) |
332,584 |
|
- |
|
Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
|
2023-11-14 |
4 |
AS |
$10.22 |
$25,366 |
D/D |
(2,482) |
346,839 |
|
-14% |
|
Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
|
2023-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
349,321 |
|
- |
|
529 Records found
|
|
Page 1 of 22 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|